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Abstract
Background: One of the characteristics of an active episode of ulcerative colitis (UC) is the intense mucosal infiltration of
leukocytes. The pro-resolution mediators Annexin-A1 (AnxA1) and lipoxin A4 (LXA4) exert counter-regulatory effects on
leukocyte recruitment, however to date, the dual/cumulative effects of these formyl peptide receptor-2 (FPR2/ALX) agonists
in the context of human intestinal diseases are unclear. To define the contribution of these mediators, we measured their
expression in biopsies from individuals with UC.
Methods: Colonic mucosal biopsies were collected from two broad patient groups: healthy volunteers without (‘Ctrl’ n = 20)
or with a prior history of UC (‘hx of UC’ n = 5); individuals with UC experiencing active disease (‘active’ n = 8), or in medically-
induced remission (‘remission’ n = 16). We assessed the mucosal expression of LXA4, AnxA1, and the FPR2/ALX receptor in
each patient group using a combination of fluorescence microscopy, biochemical and molecular analyses.
Results: Mucosal expression of LXA4 was elevated exclusively in biopsies from individuals in remission (3-fold, P,0.05 vs.
Ctrl). Moreover, in this same group we observed an upregulation of AnxA1 protein expression (2.5-fold increase vs. Ctrl,
P,.01), concurrent with an increased level of macrophage infiltration, and an elevation in FPR2/ALX mRNA (7-fold increase
vs. Ctrl, P,.05). Importantly, AnxA1 expression was not limited to cells infiltrating the lamina propria but was also detected
in epithelial cells lining the intestinal crypts.
Conclusions: Our results demonstrate a specific up-regulation of this pro-resolution circuit in individuals in remission from
UC, and suggest a significant role for LXA4 and AnxA1 in promoting mucosal homeostasis.
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Introduction
Ulcerative colitis (UC) is a relapsing disease characterized by
periods of exacerbation and remission. One of the hallmarks of an
active episode is the intense mucosal infiltration of lymphocytes,
macrophages and polymorphonuclear leukocytes (PMN) [1].
These cells release an array of injurious mediators including
proteases, cytokines and free radicals, resulting in edema, goblet
cell depletion and extensive mucosal ulceration [2,3]. Although
recruited to extinguish a pro-inflammatory stimulus, there is
emerging evidence that infiltrating leukocytes also release anti-
inflammatory mediators to trigger resolution [4,5]. Central to this
paradigm is the existence of distinct pro-resolution circuits which
modulate both the duration and intensity of the inflammatory
response [6]. Their effectiveness is governed by the timely
introduction and removal of various leukocyte subsets; for
example, during an acute inflammatory response, resolution of
inflammation is preceded by the replacement of PMNs with
macrophages. At each step these cells act as a source, or contain
the enzymatic machinery, for the synthesis of pro-resolution
mediators. A deficiency of these ‘stop-signals’, exemplified in
rodent models where such mediators are absent, results in
a persistent and dysregulated inflammatory response [7,8].
Annexin-A1 (AnxA1) is a calcium- and phospholipid-binding
protein with potent anti-inflammatory activities. It is particularly
abundant in cells of the host immune system, including monocytes,
macrophages, and PMNs [9]. Functionally, AnxA1 attenuates
leukocyte recruitment by inhibiting cell adhesion and trans-
migration [10,11]. AnxA1-deficient mice display an increased
susceptibility to dextran sodium-sulfate (DSS)-induced colitis, and
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an impaired recovery following withdrawal of DSS [12].
Important roles for AnxA1 in the regulation of mucosal re-
generation and healing have also been reported [13].
Lipoxin A4 (LXA4) is a lipoxygenase (LO)-derived eicosanoid
generated in situ by the sequential lipoxygenation of arachidonic
acid during cell-cell interaction [14,15]. LXA4 inhibits eosinophil
and PMN trafficking, adhesion and transmigration [16,17], and is
strongly chemotactic for monocytes and macrophages [18,19]; in
the latter case the ability of LXA4 to stimulate the non-phlogistic
phagocytosis of apoptotic PMNs [20,21] defines its role as an
innate modulator of resolution. Native LXA4, LXA4 analogues
and aspirin-triggered lipoxins (ATL) inhibit PMN adhesion to
intestinal epithelial cells [22,23], as well as attenuate the secretion
of chemokines from intestinal epithelia in vitro [24,25].
Both AnxA1 and LXA4 activate and signal via a common
receptor, the formyl peptide receptor 2/LXA4 receptor (FPR2/
ALX) [26]. Individually, the counter-regulatory effects of AnxA1
and LXA4 on leukocyte recruitment are abolished following
administration of FPR2/ALX antagonists [27–30], indicating the
central role of this receptor in immune-regulatory responses.
However, little is known regarding the dual or cumulative effects
of these pro-resolution mediators in human pathological settings.
In this study, we examined the possibility that AnxA1 and LXA4
exert protective and/or reparative roles in human intestinal
inflammation. Given that resolution is an active process, we
hypothesized that a microenvironment which favors a resolution
phenotype would drive an increase in levels of both these
mediators. We demonstrate that LXA4 biosynthesis is elevated
in mucosal biopsies from UC patients in medically-induced
remission. Moreover, we observed in these same patients
a concurrent up-regulation of AnxA1 in the mucosal lamina
propria and intestinal epithelia, suggesting a reparative role for
AnxA1 in healing of the intestinal mucosa. Together, these results
are consistent with a significant role, and possibly concerted
actions, for LXA4 and AnxA1 in promoting mucosal homeostasis.
Results
Proinflammatory cytokine and enzyme expression
The expression of mRNA for cytokines TNF-a, IFN-c, and IL-
1b, as well as COX-2 (Table 1), was significantly elevated in
biopsies from individuals with active disease. These findings were
consistent with the level of macroscopic inflammation described at
the time of colonoscopy. In contrast, in biopsies from individuals in
medically-induced remission the expression of all genes, but COX-
2, was not significantly different from that in the healthy group.
Mucosal infiltration by granulocytes and macrophages
Given the divergent roles of PMN and macrophages in the
inflammatory response, we next assessed the infiltration of these
cells into the colonic mucosa. PMN infiltration was significantly
elevated in biopsies from patients with active disease, as assessed
by HNE staining (Fig.1A Upper and Fig. 1B). The number of
CD68+ cells, a pan macrophage marker, was increased in biopsies
from patients with active disease, those in medically induced
remission, as well as those with a prior history of colitis (Fig. 1A
Lower and Fig. 1C). Dual-labeling of macrophages with CD68 and
CD206 revealed a significant reduction in the percentage of
alternatively activated macrophages in biopsies of those with active
disease (Fig. 1D).
Colonic LXA4 biosynthesis
LXA4 levels were significantly elevated (,3-fold) in biopsies
from patients in medically-induced remission (Fig. 2A) but not in
any of the other groups. To assess for alterations in enzymes
responsible for LXA4 biosynthesis, we first examined the mRNA
expression of LO enzymes. 5-lipoxygenase (5-LO) mRNA
expression was increased only in patients with active disease
(Fig. 2B), with no significant changes in 12-lipoxygenase (12-LO)
or 15-LO mRNA being identified (Fig. 2C and 2D, respectively).
The increase in 5-LO mRNA expression was confirmed by
immunohistochemistry (i.e., there was an increase in 5-LO+ cells in
biopsies of patients with active disease) (Fig. 2E).
AnxA1 expression in colonic mucosa
We used fluorescence microscopy to assess the expression and
localization of AnxA1 in colonic mucosal biopsies. In healthy
volunteers, a basal low level of AnxA1 expression was observed in
cells of the intestinal lamina propria (Fig. 3A, 3B). In contrast,
there was a significant increase in AnxA1 expression in biopsies
from patients with active UC or those in medically-induced
remission. Double-staining experiments revealed marked AnxA1
staining in neutrophils (co-localisation with HNE, a neutrophil
granule protease) in biopsies of patients with active disease
(Fig. 3C). In patients who were in medically-induced remission,
AnxA1 expression was associated with macrophages, as evident
from the paralleled expression with CD68 (Fig. 3D). Interestingly,
AnxA1 immunostaining in biopsies from patients with UC (active
or remission) was not limited to cells of the lamina propria, but
appeared also in some of the epithelial cells lining the intestinal
crypts (Fig. 3E). Such staining of epithelial cells was absent in
biopsies from healthy volunteers.
Many of the biological effects of AnxA1 are mediated by the
NH2-terminal domain [31,32]. It is thought that proteolytic
cleavage of the native 37 kDa protein results in termination of
Table 1. Pro-inflammatory cytokine expression.
Healthy UC
mRNA expression (fold change) Ctrl Hx of UC Active Rem
TNF-a 1.0060.46 1.0960.26 4.7761.67 * 1.1960.21
IL-1b 1.0060.47 3.5760.66 7.8761.41 * 1.3661.36
IFN-c 1.0060.43 0.9160.37 5.6161.64 Y* 1.1960.28
COX-2 1.0060.23 0.6560.16 3.9160.84 Y 3.0360.77 *
Quantitative RT-PCR analysis of pro-inflammatory cytokine and COX-2 expression in human colon biopsies. Assessment of TNF-a, IFN-c, IL-1b and COX-2 mRNA levels in
healthy subjects without (Ctrl) or with a prior history (Hx) of UC, UC patients with active disease (active), or UC patients in medically-induced remission. Data were
normalized to b-actin gene expression (n = 5–20; *P,.05 vs. Ctrl, YP,.05 vs. Hx of UC).
doi:10.1371/journal.pone.0039244.t001
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bioactivity, and cleavage-resistant AnxA1 mutants exhibit in-
creased and prolonged anti-inflammatory activities [33]. Given the
pro-inflammatory milieu in patients with active UC, we next
assessed whether the expression of AnxA1 isoforms were altered
among the patient groups. Biopsies from patients with active
disease displayed a significant increase in AnxA1 protein
Figure 1. Expression of HNE and CD68 in colonic mucosal biopsies from healthy subjects without (Ctrl) or with a prior history (Hx) of UC, or UC
patients with active disease (Active) or medically-induced remission (Rem) (A). HNE expression (Upper), used to detect PMNs was elevated in UC
patients with active disease. CD68 expression (Lower), a pan macrophage marker, was elevated in active disease as well as in medically-induced
remission. Cumulative analysis (mean counts/field) of HNE (B) and CD68 expression (C). Dual-staining of macrophage populations with CD68 and
CD206, markers for alternatively activated (M2) macrophages (D), Data are expressed as mean 6 SEM (*P,.05, ***P,.001, n = 4). Magnification
bar = 100mm.
doi:10.1371/journal.pone.0039244.g001
Figure 2. Colonic mucosal lipoxin A4 levels (A) in biopsies from healthy subjects without (Ctrl) or with a prior history (Hx) of UC, or UC patients with
active disease (Active) or medically-induced remission (Rem). Lipoxin A4 levels were significantly elevated in the samples from patients who were in
medically-induced remission compared with healthy subjects and those with a prior history of UC (.4 years disease-free). Quantitative RT-PCR
analysis of 5-LO (B), 12-LO (C) and 15-LO (D) expression revealed an increase of 5-LO expression in patients with active disease. This correlated with
an increase in the number of 5-LO-positive cells as assessed by immunohistochemistry (E). Data are expressed as fold change relative to Ctrl (*P,.05,
**P,.01 ***P,.001, n = 5–20). Magnification bar = 100 mm.
doi:10.1371/journal.pone.0039244.g002
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expression, present as a characteristic NH2-terminal-cleaved 37/
33kDa doublet (Fig. 4A, 4B). A similar increase was observed in
patients in medically-induced remission, relative to healthy
controls.
Expression of FPR2/ALX receptor
In line with colonic mucosal levels of AnxA1, analysis of FPR2/
ALX mRNA expression revealed an increase in expression in
biopsies from patients with active disease (10.763.6-fold, P,.05)
as well as in those in medically-induced remission (7.362.9-fold,
P,.05), relative to healthy controls (Fig. 5).
Discussion
Much evidence supports the capacity of infiltrating leukocytes to
synthesize, either individually or cooperatively, a number of anti-
inflammatory and pro-resolving factors [34]. In the present study,
we set out to document the contribution of a distinct pro-
resolution circuit, namely the liberation and actions of AnxA1 and
LXA4, in individuals with active or remittent UC.
Transepithelial migration of PMN from the microcirculation to
the mucosa results in impaired barrier function and destruction of
tissues [35,36]. Consistent with the literature, we observed PMN
infiltration in colonic biopsies taken from individuals with active
UC, but not in the other patient groups. Alongside the elevation in
Figure 3. Expression of Annexin-A1 in colonic mucosal biopsies from healthy subjects without (Ctrl) or with a prior history (Hx) of UC, or UC patients
with active disease (Active) or medically-induced remission (Rem) (A). Immunofluorescence detection of Annexin-A1 (red) demonstrates expression is
increased in patients with UC, whether active or in medically-induced remission. Integrated pixel intensity revealed ,3-fold increase in these groups,
compared to healthy subjects (B). In biopsies from patients with active UC, Annexin-A1 (blue) staining could be localized to infiltrating PMNs (red;
stained with anti-HNE) (C), however in biopsies from patients in medically-induced remission, Annexin-A1 staining (red) closely paralleled tissue
infiltration by CD68+ macrophages (blue; stained with anti-CD68) (D). Annexin-A1 expression was also detected in crypt epithelial cells in subjects
with UC, but not healthy subjects without/with a prior history of UC (E). Data are expressed as mean 6 SEM (*P,.05, ***P,.001, n = 4). Magnification
bar = 100 mm.
doi:10.1371/journal.pone.0039244.g003
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pro-inflammatory cytokine transcript levels (TNF-a, IFN-c and
IL-1b) and COX-2 mRNA expression, the local infiltration by cell
types such as monocytes and macrophages likely contributes to this
inflammatory milieu [37]. Intestinal macrophages play a funda-
mental role in host defense, including the phagocytosis and killing
of microorganisms. Blood monocytes recruited to the inflamed
mucosa do not display the same level of tolerogenicity as their
resident counterparts; instead, these cells retain or have increased
inflammatory capabilities [38]. Consistent with the high numbers
of PMN in biopsies from individuals with active UC, we also
observed an increase in infiltration of CD68+ macrophages. Only
a small proportion of these cells were of the M2 phenotype, as
demonstrated by dual-labeling of macrophages with CD68 and
CD206. However, the abundance of macrophages in biopsies from
individuals in medically-induced remission, where there was an
absence of PMN infiltration and an increase in COX-2 transcript
levels, likely denoting an environment that is more conducive to
the resolution of mucosal inflammation.
In a rodent model of self-resolving peritonitis, analysis of
macrophage phenotypes, specifically during the resolution phase,
revealed a new class of resolution-phase macrophages that share
markers of both classically activated and alternatively activated
cells [39]. These resolution-phase macrophages synthesize high
levels of COX-2 as well as the anti-inflammatory mediator PGD2.
We noted an increase in the number of infiltrating macrophages in
biopsies from individuals in long-term remission, previously
reported to be high producers of PGD2 [40].
Given their roles in host defense, invading leukocytes are often
viewed as pro-inflammatory. However, there is accumulating
evidence that such cells synthesize distinct counter-regulatory
mediators that promote the resolution of mucosal inflammation.
Previous studies have documented the inhibitory effects of LXA4
on leukocyte adhesion and transmigration [41,42], and LXA4
analogues have also been shown to accelerate resolution in rodent
models of colitis [43,44].
The results from our study identify a significant increase in LXA4
synthesis exclusively in biopsies from patients in medically-induced
remission. This further supports the hypothesis that there exists
a pro-resolution microenvironment in the intestinal mucosa of
individuals in remission from UC, and may be a means through
which recruited macrophages coordinate the clearance of PMN.
LXA4 synthesis has been reported in pulmonary disease [45],
periodontitis [46] and nasal polyps [47].We observed an increase in
5-LO expression, at the transcript and protein levels, in biopsies
taken from individuals with activeUC.This is consistent with known
Figure 4. Detection of annexin-A1 NH2-terminal-intact and -cleaved fragments in biopsies from healthy subjects without (Ctrl) or
with a prior history (Hx) of UC, or UC patients with active disease (Active) or medically-induced remission (Rem). Annexin-1 was
overexpressed in colonic mucosal biopsies of patients with UC compared to healthy patients with a prior history of UC (A). Alongside the native 37
kDa fragment, a NH2-terminal cleaved isoform (33 kDa) could also be visualized, indicating specific degradation in response to externalization from
activated cells. Analysis of relative intensity, where annexin-A1 immunoreactivity was normalized against b-actin (B). Data are expressed as mean 6
SEM (**P,.01, n = 5–11).
doi:10.1371/journal.pone.0039244.g004
Figure 5. mRNA expression of FPR2/ALX in colonic mucosal
biopsies from healthy subjects without (Ctrl) or with a prior
history (Hx) of UC, or UC patients with active disease (Active) or
medically-induced remission (Rem). Increased expression of FPR2/
ALX was detected in biopsies from individuals with UC. Data are
expressed as fold change relative to Ctrl (**P,.01, n = 5–12).
doi:10.1371/journal.pone.0039244.g005
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increases of leukotriene-dependent enzymes in active IBD [48].
However, we found no changes in LO expression in biopsies
obtained from individuals inmedically-induced remission.Thus, the
observed increase in mucosal LXA4 synthesis likely stems from an
augmentation of LO enzyme activity, rather than enzyme expres-
sion.
A new view regarding mechanisms of inflammatory resolution
emerged when the short-lived lipid LXA4 and the glucocorticoid-
regulated protein AnxA1 were shown to share the same receptor
target (FPR2/ALX) [49]. This indicates the existence of a conver-
gence between specific effectors for theresolution of inflammation.
Of interest, both LXA4 and AnxA1 mediate IL-10-dependent
inflammatory hyporesponsiveness in amodel of intestinal ischemia/
reperfusion injury [50]. Blockade of FPR2/ALX,LXA4 production,
and the use of neutralizing AnxA1 antibodies result in an increase in
tissue injury, TNF-a production and lethality. A direct functional
association between LXA4 and endogenous AnxA1 has recently
been described in human resting PMN in vitro [51]. However, the
association between LXA4 and AnxA1 has not been studied in man
and, more importantly, in human pathological settings. Thus,
alongside LXA4 synthesis, we determined the expression and
proteolysis of the AnxA1 in intestinal human samples.
Examination of colonic perfusates fromUCpatients indicates that
AnxA1 secretion may be dependent on the severity of inflammation
[52]. In the present study, we observed AnxA1-expression in the
colonic mucosa of healthy individuals and those with UC, although
expression was significantly elevated in the latter group. Whereas
AnxA1 was localized predominately to PMN in biopsies of
individuals with active disease, during disease remission AnxA1
expression switched to CD68+ macrophages. We speculate that
high AnxA1 levels may be a characteristic of the recently described
pro-resolving macrophages, at least in pre-clinical and clinical
models of IBD, though future studies will be needed to specifically
address this hypothesis. It is of interest to note that an increased
susceptibility, mucosal injury, and clinical morbidity is observed in
AnxA1-deficient mice administered dextran sodium sulfate (DSS)
[53]. This dysregulated inflammatory response is compounded by
an abated recovery following withdrawal of DSS administration,
thereby providing strong proof-of-concept to the pro-resolving
nature of AnxA1 in gut inflammation.
There is accumulating evidence that AnxA1 may also enhance
mucosal healing. Peptides based on the NH2-terminal region of
AnxA1 stimulate epithelial cell migration [54], which is an
important step in the restitution and wound healing process.
Gastric mucosal repair of acetic acid-induced ulcers is significantly
impaired in AnxA1-deficient mice, whereas in wild-type litter-
mates healing of the ulcer region is accompanied by an increase of
AnxA1 at the ulcer margin [55]. Rodents administered DSS also
display an increase of AnxA1 in both surface and crypt epithelial
cells [56]. When assessing colonic biopsies for the formation of
cleaved AnxA1 products by western blotting, we observed a similar
elevation of AnxA1 expression in biopsies from individuals with
UC, relative to those in the healthy group. In each case, AnxA1
was present as a 37/33kDa doublet, corresponding to the NH2-
terminal-intact and -cleaved species, respectively [57].
Another interesting observation was the up-regulation of AnxA1
in intestinal epithelial cells of biopsies from individuals with active
UC or in medically-induced remission. The increase of AnxA1
was diffuse, and not present in all crypt epithelial cells, which we
speculate is likely reflective of the degree of mucosal inflammation
and rate of cell turnover at any one point in time. This finding may
be further evidence of the reparative roles of AnxA1 in the context
of intestinal mucosa, independent of infiltrating leukocytes. It is
noteworthy though that stimulation of epithelial cell motility, while
important for mucosal healing, may also have pathophysiological
consequences if dysregulated. In line with this view, an increase of
AnxA1 expression has been associated with the development of
tumor metastasis and colonic adenocarcinoma [58–60].
As mentioned above, the effects of AnxA1 and LXA4 are
mediated via a common Gi-protein-coupled receptor, namely
FPR2/ALX [61]. FPR2/ALX is one of a family of pertussis toxin-
sensitive FPR receptors [62] that interact with structurally diverse
pro-and anti-inflammatory ligands [63]. The actions of AnxA1
and LXA4 are abolished with the use of FPR2/ALX antagonists
[64–70] as well as in FPR2/ALX-deficient mice [71], highlighting
the fundamental role of this receptor in transducing non-
redundant anti-inflammatory signals. We demonstrate herein the
up-regulation of FPR2/ALX mRNA in biopsies of UC patients in
medically-induced remission. The concurrent up-regulation of this
receptor, alongside the observed increase in synthesis of the pro-
resolution mediators AnxA1 and LXA4 is consistent with
a microenvironment that favors mucosal homeostasis. LXA4-
dependent ligation of FPR2/ALX down-regulates epithelial
secretion of the chemokine CXCL-8 [72], which likely contributes
to the reduced inflammation observed in biopsies obtained from
patients in medically-induced remission, compared to those with
active disease. No changes in FPR2/ALX expression were
observed in biopsies taken from patients with a prior history of
UC (long-term, medication-free remission for .4 years), perhaps
indicating other pro-homeostatic mechanisms are in effect [73].
In summary, this study has documented an increase in mucosal
synthesis of two pro-resolution mediators, AnxA1 and LXA4, in
individuals in medically-induced remission from UC. The
concerted up-regulation of both ligand and receptor, in a pre-
viously pro-inflammatory setting, indicates a switch to a microen-
vironment that is conducive to the resolution of inflammation.
Moreover, in the same individuals there was an up-regulation of
AnxA1 synthesis by intestinal epithelial cells, consistent with its
role in mucosal repair. We propose that this short-lived lipid and
protein/peptide pair act in concert to safeguard effective in-
flammatory resolution. It is likely that parallel or converging pro-
resolution networks, exemplified by the LXA4/AnxA1 pair, are
activated in multiple inflammatory settings, and is a scenario that
could become paradigmatic for other mediators of inflammation.
Materials and Methods
Ethics Statement
This study was approved by the Ethics Committee at the
University of Calgary. Each patient gave their written consent
prior to participation in this study and all experiments were
conducted according to the principles expressed in the Declaration
of Helsinki.
Patients and tissue samples
Colonic mucosal biopsies were obtained from two broad patient
groups: healthy individuals undergoing colonoscopy for routine
colon cancer screening, and individuals with UC. These groups
were subdivided; for healthy individuals, samples were obtained
from those with no history of UC (‘control’ group; n = 8 male and
12 female; mean age 5169 years), or those diagnosed previously
with UC but had not experienced any bout of disease nor required
any medication for UC for at least 4 years (‘prior history of UC’
group; n = 5 female; mean age 47611 years). Patients with UC
were divided into two groups: those with active disease (‘active’
group; n = 5 male and 3 female; mean age 43616 years), and
those in clinical and endoscopic remission while on maintenance
therapy with either oral/topical 5-aminosalicylic acid or immu-
Synthesis of Pro-Resolution Mediators in Colitis
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39244
nosuppressive/ biological therapy (‘remission’ group; n= 9 male
and 7 female; mean age 44613 years). Details regarding patient
characteristics, such as gender, age, and clinical activity were
obtained from medical records. Mucosal biopsies were taken from
the left colon in close proximity to biopsies used for histological
assessment. Samples intended for quantitative PCR, LXA4
measurement, or western blotting were stored at 280uC until
ready for processing. Samples for immunohistochemistry were
fixed in 10% neutral-buffered formalin.
Quantitative PCR
Total RNA from colonic biopsies was extracted using the
RNeasy Mini Kit (Qiagen, Valencia, CA) and two-step quantita-
tive PCR was performed, as described [74]. Bioinformatic-
validated high efficiency primer assays for human TNF-
a (NM_000594), IL-1b (NM_000576), IFN-c (NM_000619),
COX-2 (NM_000963), 5-LO (NM_000698), 12-LO
(NM_000697), 15-LO (NM_001140), FPR2/ALX (NM_001462)
and b-actin (NM_001101) were obtained from Qiagen (Valencia,
CA). All data were analyzed using Ct values obtained from
Realplex software (Eppendorf, Ontario, CA), and amplification
and relative quantification of gene products determined using the
DDCt method, where target genes were normalized against the
housekeeping gene b-actin.
Western blotting
Tissue samples were processed and proteins separated by 12%
SDS-PAGE, as described previously [75]. Primary polyclonal
rabbit anti-AnxA1 (Invitrogen) and monoclonal mouse anti-b-
actin (Sigma Aldrich) antibodies were used. Secondary anti-rabbit
and anti-mouse IgG antibodies were conjugated to horseradish
peroxidase (GE Healthcare), and visualized using enhanced
chemiluminescence (ECL) detection kit (GE Healthcare) on
a Chemi-doc gel imaging system (Bio-Rad). Densitometric analysis
was performed using ImageLab 2.0 software (Bio-Rad, Ontario,
CA), with AnxA1 protein normalized against b-actin expression.
Histology and immunohistochemical analysis
Colonic biopsies from four patients per group were used for
immunohistochemistry. For analysis of HNE and CD68 (markers
of PMNs and macrophages, respectively), or 5-LO expression,
sections were incubated in 3% H2O2 for 15min and then steamed
for 30min in 10mM citrate buffer (pH 6.0)/0.05% Triton X-100.
Sections were blocked in 10% normal serum, and incubated with
mouse anti-human HNE (clone NP57, DAKO Cytomation),
mouse anti-human CD68 (clone PG-M1, DAKO), mouse anti-
human CD206 (ABCAM) or rabbit anti-5-LO (Cayman Chemi-
cal) overnight at 4uC. Sections were washed in PBS, incubated
with anti-mouse or anti-rabbit biotinylated secondary antibodies
(Vector Laboratories), and visualized by avidin-biotin-peroxidase
detection using the Vectastain Elite ABC kit (Vector Laboratories).
3–39 diaminobenzidine (DAB; Vector Laboratories) was used as
the chromagen, and sections counterstained with Mayer’s
hematoxylin (Sigma Aldrich). For immunofluorescence detection
of AnxA1, sections were blocked with 3% BSA and incubated with
a monoclonal antibody raised against full-length human AnxA1
(mAb1B [76]) overnight, 4uC. To examine co-localization of
AnxA1 with HNE or CD68, rabbit anti-AnxA1 antibody
(Invitrogen) was incubated alongside anti-HNE or anti-CD68
antibodies. Sections were washed and incubated with Alexa-
FluorH568 goat anti-mouse IgG, AlexaFluorH350 goat anti-mouse
IgG, AlexaFluorH568 goat anti-rabbit IgG, or AlexaFluorH350
goat anti-rabbit IgG (Invitrogen). To examine co-localization of
CD68 with CD206, sections were incubated with AlexaFlourH568
goat anti-mouse and AlexaFluorH488 goat anti-mouse, respective-
ly. Sections were then mounted with ProLong Gold containing
DAPI (Invitrogen) or Vectashield fluorescence mounting medium
(Vector Laboratories). Fluorescence was visualized on a Nikon
Eclipse 80i microscope (Nikon) equipped with a DS-QiMc
monochromatic camera (Nikon) and X-CiteH Series 120Q Xenon
lamp. NIS-Elements BR3.1 software (Nikon) was used for all
analyses. Images were recorded at identical gain settings, and
mean intensity calculated per image field. Four image fields were
taken of each section.
Lipoxin A4 measurement
Measurement of LXA4 was performed, as previously described
[77], using a commercially available LXA4 ELISA kit (Oxford
Biomedical Research, Canada). Briefly, colonic biopsies were
homogenized in extraction buffer (isopropranol/ethanol/0.1N
HCl; 3:3:1), and diluted 1:1 with deionized water. The sample
was centrifuged at 1,500g for 10min at 4uC, the organic phase
transferred to a new tube, acidified to pH 3.5 and purified on pre-
conditioned C18 Sep-Pak light columns (Millipore). The eluate
was evaporated to dryness under a gentle stream of nitrogen gas
and levels of LXA4 determined using a commercially available
LXA4 ELISA kit (Oxford Biomedical Research, Canada).
Statistical analysis
Data are presented as mean6SEM. Comparisons among
groups of data were made using a one-way ANOVA followed
by the Kruskal-Wallis test. An associated probability (P,.05) was
considered significant.
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